News

b

b

Current News in Drug Discovery

RSS Nature Reviews Drug Discovery
  • RNA modification systems as therapeutic targets September 17, 2025
    Nature Reviews Drug Discovery, Published online: 17 September 2025; doi:10.1038/s41573-025-01280-8RNA can be chemically modified by enzymes such as methyltransferases to regulate RNA metabolism, gene expression and other biological processes. This Review mainly focuses on the disease-relevant N6-methyladenosine RNA modification pathway and discusses efforts to therapeutically target N6-methyladenosine writer, eraser and reader proteins.
    Linda Zhang
  • Upcoming FDA approval decisions in Q4 2025 September 15, 2025
    Nature Reviews Drug Discovery, Published online: 15 September 2025; doi:10.1038/d41573-025-00152-5Upcoming FDA approval decisions in Q4 2025
    Kaniaw Dilzer
  • Microsystem technologies for accelerating the discovery and translation of immunotherapies September 15, 2025
    Nature Reviews Drug Discovery, Published online: 15 September 2025; doi:10.1038/s41573-025-01268-4The potential of microsystem technologies to accelerate the development and clinical translation of immunotherapies is now being realized. This Review discusses recent advances in microsystem technologies, illustrating how their application can address key challenges related to the efficacy, toxicity, predictability and affordability of immunotherapeutics. Future directions […]
    Zongjie Wang
  • New US$3.1 billion foundation takes big, long-term bets on bioscience, AI and the environment September 12, 2025
    Nature Reviews Drug Discovery, Published online: 12 September 2025; doi:10.1038/d41573-025-00154-3Lynda Stuart, president and CEO of the newly launched Fund for Science and Technology, discusses the philanthropic organization’s plans for bioscience and AI.
    Asher Mullard
  • Breakthrough therapy designations in China and the United States September 12, 2025
    Nature Reviews Drug Discovery, Published online: 12 September 2025; doi:10.1038/d41573-025-00153-4Breakthrough therapy designations in China and the United States
    Xiangyun Mao
  • Synthetic lethality in cancer drug discovery: challenges and opportunities September 11, 2025
    Nature Reviews Drug Discovery, Published online: 11 September 2025; doi:10.1038/s41573-025-01273-7This Review outlines recent advances in synthetic lethality, from CRISPR-based discovery and machine learning-guided prioritization of gene pairs to new phenotypic readouts, highlighting emerging strategies to overcome translational barriers and unlock the therapeutic potential of targeting context-specific genetic dependencies in cancer.
    Emanuel Gonçalves
  • Novel drug candidates for hard-to-treat hypertension vie for blockbuster positioning September 8, 2025
    Nature Reviews Drug Discovery, Published online: 08 September 2025; doi:10.1038/d41573-025-00150-7Novel drug candidates for hard-to-treat hypertension vie for blockbuster positioning
    Asher Mullard
  • FDA approves anti-prekallikrein drug for hereditary angioedema September 8, 2025
    Nature Reviews Drug Discovery, Published online: 08 September 2025; doi:10.1038/d41573-025-00151-6FDA approves anti-prekallikrein drug for hereditary angioedema
    Asher Mullard

Vitreon America™ Launches Botanicopeia™ Database and Federal Government Services at NIH Festival+

 BETHESDA, MD, September 17, 2016 − Vitreon America, Inc.™ participated this week in the National Institute of Health (NIH) Intramural Research Program’s 30th Annual NIH Research Festival which was held September 15-16, 2016 at the NIH Bethesda, Maryland campus.

The Festival included plenary sessions, symposia, exhibits, poster sessions and tours designed to encourage sharing and learning about the exciting research taking place on NIH campus.

Vitreon America™ was selected by the Technical Sales Association (TSA) which sponsors the Research Festival Exhibit, to launch its state-of-the-art Phytochemical and Ethnobotanical database subscription services, Botanicopeia™.

Attending on behalf of Vitreon America™
were Michael Megginson, VP of Business Development (left) and Jorgen Sandberg,
CEO (right).

Vitreon America was pleased to see the interest from the NIH Institutions to utilize the Botanicopeia™ database subscriptions with many NIH researchers expressing interest in considering the Vitreon America Botanical Research Analytic services as well to optimize the Botanicopeia™ database.

Based on the NIH researchers feedback, Vitreon America has established a Botanicopeia™ database subscription service agreement and subscription service with botanical research analytic services through Marshall Communications Corporation, www.marshallcomm.com.

Vitreon America services are available through Marshall Communications Corporation (VOSB) on NIH’s Information Technology Acquisition and Assessment Center’s (NITAAC)- Government-wide Acquisition Contract (GWAC) vehicle. [Prime Contract Holder #HHSN316201500063W]

Vitreon America™ was established with the goal of commercializing their Botanicopeia™ database and botanical research analytic services for development of botanicals and phytochemicals in the creation of new medicinal products by Vitreon America Clients.

To find out more about our Services please contact us for assistance at 1-888-214-2584 or at info@vitreonamerica.com

About Vitreon America™

Vitreon AmericaTM was formed with the goal of disseminating their BotanicopeiaTM database to encourage the increased use of botanicals and phytochemicals in the creation of new medicines.

Contact Vitreon America, Inc.

Vitreon America Botanical Research Center @ Hopkins Johns Hopkins University

MCC 9601 Medical Center Drive, Suite 221
Rockville, Maryland 20850

+1-888-214-2584

j.shaver@advasur.com